Use of direct oral anticoagulants after transcatheter aortic valve replacement

Andrea Scotti; Mauro Massussi; Antonio Landi; George Besis

doi:10.1007/978-3-030-74462-5_15

Use of direct oral anticoagulants after transcatheter aortic valve replacement

Andrea Scotti
, Mauro Massussi
, Antonio Landi
, George Besis

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Transcatheter aortic valve replacement (TAVR) is a well-established procedure which shares common features with percutaneous coronary intervention and surgical aortic valve replacement. Technical and clinical aspects influence the appropriate antithrombotic strategy. Anticoagulation management is a priority in patients with atrial fibrillation and may have a role in preventing bioprosthetic valve thrombosis. In this chapter, we will offer a summary of published studies, current recommendations, and future perspectives on optimal medical therapy after TAVR.

Original language	English (US)
Title of host publication	Direct Oral Anticoagulants
Subtitle of host publication	From Pharmacology to Clinical Practice
Publisher	Springer International Publishing
Pages	247-254
Number of pages	8
ISBN (Electronic)	9783030744625
ISBN (Print)	9783030744618
DOIs	https://doi.org/10.1007/978-3-030-74462-5_15
State	Published - Jun 28 2021
Externally published	Yes

Keywords

Antithrombotic therapy
Atrial fibrillation
Bleeding risk
Cerebrovascular accident
Direct oral anticoagulants
Percutaneous coronary intervention
Subclinical leaflet thrombosis
Thrombotic risk
Transcatheter aortic valve replacement

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-74462-5_15

Cite this

@inbook{db57ef674f1c4fe7ab8e5ada84365203,

title = "Use of direct oral anticoagulants after transcatheter aortic valve replacement",

abstract = "Transcatheter aortic valve replacement (TAVR) is a well-established procedure which shares common features with percutaneous coronary intervention and surgical aortic valve replacement. Technical and clinical aspects influence the appropriate antithrombotic strategy. Anticoagulation management is a priority in patients with atrial fibrillation and may have a role in preventing bioprosthetic valve thrombosis. In this chapter, we will offer a summary of published studies, current recommendations, and future perspectives on optimal medical therapy after TAVR.",

keywords = "Antithrombotic therapy, Atrial fibrillation, Bleeding risk, Cerebrovascular accident, Direct oral anticoagulants, Percutaneous coronary intervention, Subclinical leaflet thrombosis, Thrombotic risk, Transcatheter aortic valve replacement",

author = "Andrea Scotti and Mauro Massussi and Antonio Landi and George Besis",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2021",

month = jun,

day = "28",

doi = "10.1007/978-3-030-74462-5\_15",

language = "English (US)",

isbn = "9783030744618",

pages = "247--254",

booktitle = "Direct Oral Anticoagulants",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Use of direct oral anticoagulants after transcatheter aortic valve replacement

AU - Scotti, Andrea

AU - Massussi, Mauro

AU - Landi, Antonio

AU - Besis, George

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2021.

PY - 2021/6/28

Y1 - 2021/6/28

N2 - Transcatheter aortic valve replacement (TAVR) is a well-established procedure which shares common features with percutaneous coronary intervention and surgical aortic valve replacement. Technical and clinical aspects influence the appropriate antithrombotic strategy. Anticoagulation management is a priority in patients with atrial fibrillation and may have a role in preventing bioprosthetic valve thrombosis. In this chapter, we will offer a summary of published studies, current recommendations, and future perspectives on optimal medical therapy after TAVR.

AB - Transcatheter aortic valve replacement (TAVR) is a well-established procedure which shares common features with percutaneous coronary intervention and surgical aortic valve replacement. Technical and clinical aspects influence the appropriate antithrombotic strategy. Anticoagulation management is a priority in patients with atrial fibrillation and may have a role in preventing bioprosthetic valve thrombosis. In this chapter, we will offer a summary of published studies, current recommendations, and future perspectives on optimal medical therapy after TAVR.

KW - Antithrombotic therapy

KW - Atrial fibrillation

KW - Bleeding risk

KW - Cerebrovascular accident

KW - Direct oral anticoagulants

KW - Percutaneous coronary intervention

KW - Subclinical leaflet thrombosis

KW - Thrombotic risk

KW - Transcatheter aortic valve replacement

UR - https://www.scopus.com/pages/publications/85149188667

UR - https://www.scopus.com/pages/publications/85149188667#tab=citedBy

U2 - 10.1007/978-3-030-74462-5_15

DO - 10.1007/978-3-030-74462-5_15

M3 - Chapter

AN - SCOPUS:85149188667

SN - 9783030744618

SP - 247

EP - 254

BT - Direct Oral Anticoagulants

PB - Springer International Publishing

ER -

Use of direct oral anticoagulants after transcatheter aortic valve replacement

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this